How to Get Semaglutide Online: The Process and the Red Flags
Getting semaglutide online usually means an intake form, a clinician review, and a prescription routed to a pharmacy. Most states do not accept a questionnaire alone, LillyDirect-listed visits run $25/visit to $149/month excluding medication, and some services sell compounded drugs that are not FDA-approved.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Getting semaglutide prescribed online generally follows the same five steps: you fill out an intake questionnaire, a licensed clinician reviews it (sometimes with a video or chat visit), the clinician either writes a prescription or declines, the prescription is routed to a pharmacy, and the medication ships to you with follow-up visits and refills handled through the platform. Telehealth GLP-1 services come in two billing models — self-pay and insurance-billed — and the options listed on Lilly’s obesity telehealth page run from $25/visit to $149/month for the visit or membership itself, with medication priced separately [7].
The hard part is not the process; it is telling a legitimate service from a sketchy one. The main things to verify are whether the clinician is licensed in your state, whether you are getting an FDA-approved brand or a compounded copy, which pharmacy actually fills the order, and what the total cost and cancellation terms are before you pay. Federal regulators have taken action on several of those points: the FDA has warned telehealth companies over false claims about compounded GLP-1s [2][4], and the FTC finalized an order on December 3, 2025 against a telemedicine company over hidden costs and cancellation practices [5].
Do you need a prescription for semaglutide?
Yes. Semaglutide products are prescription drugs, and a patient-provider relationship is needed to write a prescription in most states [1]. What varies is how that relationship can be established online, and that is governed state by state.
Most states consider using only an internet or online questionnaire to establish the patient-provider relationship needed to write a prescription as inadequate [1]. Some states require a physical exam before a prescription is written, though not all require that exam to happen in person — some specifically allow telehealth to conduct it [1]. So a service that promises a prescription from a form alone may not be operating legally in your state. Rules differ across states, and the Center for Connected Health Policy, which tracks these rules, advises checking with the appropriate state agency and notes its material is not legal advice [1].
Do DEA telemedicine rules apply to online prescriptions?
As general background on federal rules for scheduled drugs: the DEA’s temporary telemedicine flexibility authorizes a DEA-registered practitioner to prescribe schedule II–V controlled substances via telemedicine without a prior in-person medical evaluation during the period May 12, 2023 through December 31, 2026, when conditions are met [1]. Those conditions include a legitimate medical purpose by a practitioner acting in the usual course of professional practice, and a communication between practitioner and patient using an interactive telecommunications system as referred to in 42 CFR 410.78(a)(3) [1]. The authorization expires at the end of December 31, 2026 [1].
A special DEA telemedicine registration requires the practitioner to be registered in the state where the patient will be located when receiving telemedicine treatment [1]. Separately, the effective dates of the buprenorphine-via-telemedicine and VA continuity-of-care rules were delayed to December 31, 2025 [1]. These are rules for scheduled drugs generally, not a statement about any particular drug’s scheduling status. For non-controlled prescriptions, the governing rules are state-level, and the nuances differ across states [1].
Can a telehealth doctor prescribe Ozempic or Wegovy?
Whether a telehealth clinician can prescribe depends on your state’s rules on establishing the patient-provider relationship, which vary state to state [1]. Your state medical board is the place to confirm what applies where you live.
What the manufacturers do is route patients to telehealth. Novo Nordisk’s NovoCare site lists independent telehealth providers it describes as “recognized by Novo Nordisk for legitimate medicine sourcing and patient support” [6]. Lilly’s LillyDirect page lists independent providers for obesity care [7]. Neither listing is an endorsement. Novo Nordisk states it operates independently, does not endorse the listed providers, receives no compensation for referrals, and makes no representations or guarantees about any provider’s qualifications or the appropriateness of any treatment [6]. Lilly says the providers apply their own independent clinical judgment to decide if medication is right for you, and that Lilly does not endorse or recommend them [7]. Treat both lists as directories, not seals of approval.
What does the online process look like step by step?
The typical flow is intake form, clinician review, prescription routed to a pharmacy, shipment, then follow-up and refills. How fast the first visit happens varies a lot. Among the providers listed on Lilly’s obesity telehealth page, the average time to a first visit ranges from 15 minutes (Counsel Health) to 10 days (knownwell), with General Medicine at 12 hours, Sesame at 1 hour, and WeightWatchers at 2 days [7].
Some services work through chat rather than video. Counsel Health describes its model as chat-first: medical AI gathers context, then a physician joins to evaluate and prescribe [7]. Whether a service can evaluate and prescribe without a live video visit depends on your state’s rules on establishing the patient-provider relationship [1].
How much do online GLP-1 visits and memberships cost?
The LillyDirect obesity telehealth page lists five options from $25/visit to $149/month. Those rates are self-reported by the providers, may vary, and exclude medication costs entirely [7].
| Provider (LillyDirect listing) | Billing | Price | Annual pricing | Avg. time to first visit |
|---|---|---|---|---|
| General Medicine | Insurance (commercial, Medicare, Medicaid) or self-pay | $25/visit avg. with insurance; $30 per chat visit self-pay | — | 12 hours |
| Counsel Health | Self-pay only | $29/visit | $25/month | 15 minutes |
| Sesame | Self-pay only | $99/month | $59/month | 1 hour |
| WeightWatchers | Self-pay | $149/month | $74/month | 2 days |
| knownwell | Insurance (commercial, Medicare) or self-pay | $31/visit avg. with insurance; $299 per visit self-pay | — | 10 days |
All figures are as listed by Lilly and exclude medication cost [7]. The listed providers can also support eligible Medicare Part D patients through the Medicare GLP-1 Bridge program [7]. On the NovoCare side, listed telehealth options include 9amHealth, EMed, Form Health, KnownWell, LifeMD, Ro, Sesame, and WeightWatchers, with payment options including insurance, HSA/FSA, and cash [6].
What is the difference between brand-name and compounded semaglutide?
This is the single most important question, because what ships to your door is not always what the ads imply. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before marketing [2]. Generic drugs, by contrast, are FDA-approved before marketing — so calling a compounded drug a “generic version” of Wegovy or Ozempic is false and misleading, according to the FDA [2].
Compounded products must meet the conditions of section 503A or 503B of the Federal Food, Drug, and Cosmetic Act in order to be exempt from certain requirements under the Act, including the new-drug approval requirements [4]. The FDA does not approve or license any compounding pharmacy or outsourcing facility, so any service claiming its compounded drug comes from an “FDA-approved” or “FDA-licensed” pharmacy is making a false claim [2].
Who actually makes the compounded semaglutide, and can you find out?
Often you cannot tell — and that is a documented problem. On February 20, 2026, the FDA warned MEDVi, LLC of Newark, Delaware, that its website labels pictured “MEDVi” on compounded semaglutide and tirzepatide products, implying MEDVi was the compounder when it was not. The FDA found this misbranded the products under sections 502(a) and 502(bb) of the FDCA [4].
MEDVi was also cited for claims like “Same active ingredient as Wegovy® and Ozempic®” and “Same active ingredient as Mounjaro® and Zepbound®,” which the FDA said falsely imply the products were FDA-approved or evaluated for safety and effectiveness [4]. The FDA gave MEDVi 15 working days to respond and asked it to identify the entities actually producing the products [4]. The lesson for a buyer: if a telehealth brand puts its own name on the vial, that does not mean it made the drug, and you may have no way of knowing who did.
How do you check a compounding pharmacy’s record with the FDA?
The FDA publishes “Compounding: Inspections, Recalls, and other Actions,” an A-to-Z list of compounders with Form 483 inspection observations, warning letters, untitled letters, state referral letters, and FMD-145 letters. Each entry flags whether the facility is a 503A pharmacy or an outsourcing facility [3]. Compounding recalls are searchable in the FDA Enforcement Report [3].
You can also search the term “telehealth” in the FDA’s warning letter database to find warning letters issued to telehealth companies specifically [2][3]. Before ordering compounded medication, ask the service which pharmacy fills the prescription, then look that pharmacy up in the FDA list. If the service will not name the pharmacy, that is a reason to walk away.
What red flags should make you walk away?
The FDA has spelled out the claims it considers false or misleading when telehealth companies promote compounded GLP-1s [2]:
- Branding that implies the telehealth company itself is the compounder
- Describing a compounded drug as a generic version of an FDA-approved drug, or “the same as” one
- Claiming a compounded drug is FDA-approved or has been evaluated for safety and effectiveness
- Claiming a compounded drug is clinically proven to produce the same result as the approved drug
- Claiming the drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility
The FDA says such claims violate federal law and leave patients unable to make informed decisions [2].
A separate category is “research use only” peptide sellers. On March 31, 2026, the FDA warned Gram Peptides of Rancho Santa Fe, California, over retatrutide, tirzepatide, and bacteriostatic water offered for sale on its website [8]. The site’s “Research Use Only” and “not intended for human consumption” disclaimers did not stop the FDA from finding the products were intended for human drug use, based on the website’s own claims about weight loss and glucose effects [8]. The FDA deemed those products unapproved new drugs under section 505(a) of the FD&C Act, and selling them violates sections 301(d) and 505(a) [8]. The FDA’s stated concern with injectables sold online is that injections bypass the body’s defenses against toxins and microorganisms, posing a risk of serious harm [8]. Vial-based products that require reconstitution are often sold alongside bacteriostatic water, as in the Gram Peptides case [8].
What can go wrong with billing and cancellation?
The FTC’s case against NextMed shows the pattern to watch for. The FTC’s July 2025 complaint alleged that NextMed and its principals Robert Epstein and Frank Leonardo sold GLP-1 weight-loss programs with undisclosed costs and membership commitments, made unsubstantiated weight-loss claims, used fake testimonials, distorted consumer reviews, failed to process cancellations and refunds on time, and charged consumers without express informed consent [5].
The final order, approved December 3, 2025 by a 2-0 Commission vote, requires a $150,000 payment expected to fund consumer refunds, and mandates clear disclosure of refund and cancellation terms before payment, a simple way to request cancellations or refunds, prompt honoring of those requests, informed consent before billing, authorization for electronic fund transfers, evidence behind typical-results claims, and no review manipulation [5]. Before you pay any service, get the total monthly cost and the exact cancellation steps in writing.
Does it matter who owns the telehealth platform?
It can come up. Telehealth companies have been sued over selling compounded GLP-1 drugs and alleged violations of corporate practice of medicine laws [9]. For a buyer, the practical relevance is knowing whether the clinician making the prescribing decision is independent of the company selling the medication. If the marketing feels like it is steering you toward a specific product rather than an evaluation, that structure is worth asking about.
Where do you report a problem?
The FDA has logged more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide [10]. Compounding concerns can be reported to the FDA at compoundinginspections@fda.hhs.gov, the office that handles compounding compliance [4]. The FDA also makes state referrals to state boards of pharmacy when it finds problems at a compounder [3]. Billing and cancellation problems can be reported at ReportFraud.ftc.gov [5].
What three questions should you settle before paying?
- Am I getting an FDA-approved brand or a compounded copy? Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing [2].
- Which pharmacy fills it, and what is its FDA record? Ask for the pharmacy’s name and check it against the FDA’s compounding inspections and recalls list [3][4].
- What is the total monthly cost, and what are the exact cancellation mechanics? Both should be disclosed before you pay anything [5][7].
These three questions are consumer-side due diligence, not a compliance test. But the FTC’s NextMed complaint shows what can happen when they go unanswered: undisclosed costs and membership commitments were among the allegations, and the final order now requires that provider to disclose refund and cancellation terms before payment [5]. If a service will not put those answers in writing before you pay, that is the point to walk away and report the practice at ReportFraud.ftc.gov [5].
Sources
- Center for Connected Health Policy. State telehealth policies for online prescribing.
- US Food and Drug Administration. FDA to telehealth companies: what to know when promoting compounded drugs.
- US Food and Drug Administration. Compounding: inspections, recalls, and other actions.
- US Food and Drug Administration. Warning letter: MEDVi, LLC dba MEDVi. February 20, 2026.
- Federal Trade Commission. FTC approves final order against telehealth provider NextMed over charges it used deceptive advertising claims to sell GLP-1 weight-loss programs. December 2025.
- NovoCare. Find a doctor to help with weight loss treatment.
- LillyDirect. Telehealth for obesity.
- US Food and Drug Administration. Warning letter: Gram Peptides. March 31, 2026.
- Wilson Sonsini. Telehealth companies sued for selling compounded GLP-1 drugs and violations of corporate practice of medicine laws. May 5, 2025.
- Drug Discovery and Development. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide.
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
Frequently asked questions
Is buying semaglutide online legal?
That depends on state law, which varies. Most states consider an online questionnaire alone inadequate to establish the patient-provider relationship needed to write a prescription, and some require an exam, though not all require it in person. CCHP, which tracks these policies, notes its material is not legal advice and advises checking with the appropriate state agency.
Does my state require a live video visit, or is a questionnaire enough?
It depends on the state. Most states treat an internet questionnaire alone as inadequate to establish the patient-provider relationship needed to write a prescription. Some states require a physical exam first, but not all require it in person, and some specifically allow telehealth to conduct the exam. CCHP, which tracks these policies, advises contacting the appropriate state agency.
Can a doctor licensed in another state prescribe to me?
For non-controlled prescriptions, the governing rules are state-level and the nuances differ across states. DEA rules for scheduled drugs add their own location requirements — a special telemedicine registration requires registration in the state where the patient is located when receiving treatment. Because the rules vary, check with your state's medical board before the visit.
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. The FDA states that calling a compounded drug a generic version of an FDA-approved drug, or the same as one, is false and misleading, since generics are FDA-approved before marketing and compounded drugs are not.
How do I check whether a compounding pharmacy has been cited or recalled?
Search the pharmacy's name in the FDA's "Compounding: Inspections, Recalls, and other Actions" list, which shows Form 483s, warning letters, untitled letters, state referral letters, and FMD-145 letters, and flags 503A versus outsourcing facility status. Compounding recalls are searchable in the FDA Enforcement Report.
What does 503A vs 503B mean for the vial I receive?
Compounded products must meet the conditions of section 503A or 503B of the FD&C Act to be exempt from certain requirements under the Act, including the new-drug approval requirements. The FDA's compounding actions list flags whether a facility is a 503A pharmacy or an outsourcing facility. Neither status means FDA approval — the FDA does not approve or license any compounding pharmacy or outsourcing facility.
What did the FDA find about 'research use only' retatrutide and tirzepatide sold online?
The FDA warned Gram Peptides on March 31, 2026 that its retatrutide, tirzepatide, and bacteriostatic water products were unapproved new drugs under section 505(a) of the FD&C Act, and that selling them violates sections 301(d) and 505(a). "Research Use Only" and "not for human consumption" disclaimers did not change that finding, which the FDA based on the website's own claims.
What telehealth services do Novo Nordisk and Lilly list?
NovoCare lists 9amHealth, EMed, Form Health, KnownWell, LifeMD, Ro, Sesame, and WeightWatchers. LillyDirect lists General Medicine, Counsel Health, Sesame, WeightWatchers, and knownwell. Neither company endorses these providers — both expressly disclaim endorsement and say providers apply independent clinical judgment.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.